辛伐他汀對(duì)腦梗死患者神經(jīng)功能及預(yù)后的影響
[Abstract]:Objective: to investigate the effect of simvastatin on neurological function and prognosis in patients with cerebral infarction. Methods: 82 patients with cerebral infarction from January 2015 to July 2016 were randomly divided into observation group (n = 41) and control group (n = 41). The control group received routine thrombolytic therapy and oral aspirin enteric-coated tablets for 10 mg,qd. the observation group took simvastatin tablets before bedtime on the basis of control group for 10 mg,qd.. After one month of treatment, the prognosis, incidence of adverse events and (NIHSS) score of stroke scale before and after treatment were compared between the two groups. The clinical data of the two groups were analyzed by multivariate Logistic regression analysis. Results: the good prognosis rate of the patients in the observation group was 80.49, which was significantly higher than that in the control group (68.29%, P0.05). The incidence of intracranial and extracranial vascular stenosis, cerebrocardiac syndrome and death in the observation group were 36.599.51 and 19.51, respectively, which were significantly lower than those in the control group (46.3436.597.32). The difference was statistically significant (P0.05). Before treatment, there was no significant difference in NIHSS score between the two groups (P0.05); after one month of treatment, the NIHSS score of the two groups decreased significantly, and the observation group was significantly lower than the control group, the difference was statistically significant (P0.05). The age of 65 years, NIHSS score at admission, diabetes mellitus, and no statins were independent risk factors for the survival status of patients with cerebral infarction (P0.05). Conclusion: simvastatin can significantly improve the prognosis of patients with cerebral infarction, improve the neurological function, reduce the incidence of adverse events, and no use of statins is an independent risk factor affecting the survival of patients.
【作者單位】: 湖北省中醫(yī)院光谷院區(qū)急診內(nèi)科;
【分類號(hào)】:R743.33
【相似文獻(xiàn)】
中國(guó)期刊全文數(shù)據(jù)庫 前10條
1 Rajabally Y.A.,Varakantam V. ,Abbott R.J. ,袁海峰;他汀類藥物治療引發(fā)類格林-巴利綜合征[J];世界核心醫(yī)學(xué)期刊文摘(神經(jīng)病學(xué)分冊(cè));2005年03期
2 高連波;楊健;陳軍;賈劉辛;;他汀類藥物防治卒中的研究進(jìn)展[J];中國(guó)卒中雜志;2006年10期
3 韓秀霞;;他汀類藥物可降低卒中危險(xiǎn)[J];國(guó)外醫(yī)學(xué)情報(bào);1998年09期
4 冀玉靜;;他汀類藥物可降低卒中的危險(xiǎn)性[J];國(guó)外醫(yī)學(xué)情報(bào);2004年09期
5 張茁,高天理;他汀類藥物預(yù)防卒中的新證據(jù)[J];繼續(xù)醫(yī)學(xué)教育;2005年09期
6 凌鋒;;重視他汀類藥物對(duì)卒中預(yù)防的作用[J];中國(guó)腦血管病雜志;2006年05期
7 欒文忠;;他汀類藥物在卒中預(yù)防和治療中的應(yīng)用[J];中國(guó)腦血管病雜志;2007年04期
8 喬曼麗;;他汀類藥物與卒中[J];中華腦血管病雜志(電子版);2008年03期
9 尹繼君;林峰;王高臨;孟范文;王新強(qiáng);;他汀類藥物干預(yù)頸動(dòng)脈粥樣硬化斑塊研究進(jìn)展[J];腦與神經(jīng)疾病雜志;2010年03期
10 張麗芳;;老年人的他汀類藥物治療[J];中國(guó)全科醫(yī)學(xué);2012年14期
中國(guó)重要會(huì)議論文全文數(shù)據(jù)庫 前1條
1 袁勝山;張駿;余昌胤;;他汀類藥物與缺血性腦血管疾病的研究進(jìn)展[A];2006年貴州省醫(yī)學(xué)會(huì)神經(jīng)病學(xué)分會(huì)學(xué)術(shù)年會(huì)論文匯編[C];2006年
中國(guó)重要報(bào)紙全文數(shù)據(jù)庫 前2條
1 白毅;構(gòu)筑預(yù)防卒中復(fù)發(fā)的防線[N];中國(guó)醫(yī)藥報(bào);2007年
2 本報(bào)特約撰稿人 陸志城;他汀類藥物可降低腦卒中復(fù)發(fā)率[N];醫(yī)藥經(jīng)濟(jì)報(bào);2006年
中國(guó)碩士學(xué)位論文全文數(shù)據(jù)庫 前10條
1 蔡麗敏;阿伐他汀單用及與輔酶Q10聯(lián)用對(duì)急性腦卒中血脂和肝功能的影響[D];泰山醫(yī)學(xué)院;2014年
2 張曉鑫;他汀類藥物對(duì)缺血性腦卒中病人溶栓后癥狀性顱內(nèi)出血的影響的Meta分析[D];新鄉(xiāng)醫(yī)學(xué)院;2015年
3 王雯;他汀類藥物預(yù)防腦卒中的18項(xiàng)隨機(jī)對(duì)照試驗(yàn)的Meta分析[D];大連醫(yī)科大學(xué);2015年
4 唐林云;他汀類藥物對(duì)急性缺血性腦卒中后感染患者功能預(yù)后的影響[D];東南大學(xué);2016年
5 盧璐;他汀類藥物對(duì)蛛網(wǎng)膜下腔出血干預(yù)作用的meta分析[D];鄭州大學(xué);2016年
6 趙悅;他汀類藥物對(duì)缺血性腦血管病患者體液免疫指標(biāo)的調(diào)節(jié)作用[D];山東大學(xué);2014年
7 郭佳;他汀類藥物預(yù)防卒中再發(fā)的系統(tǒng)評(píng)價(jià)[D];蘭州大學(xué);2009年
8 羅生輝;他汀類藥物對(duì)急性缺血性腦卒中患者外周血造血干細(xì)胞的影響及其意義[D];福建醫(yī)科大學(xué);2010年
9 陳文倩;他汀類藥物聯(lián)合干擾素治療對(duì)復(fù)發(fā)緩解型多發(fā)性硬化患者緩解期影響的系統(tǒng)評(píng)價(jià)[D];廣西醫(yī)科大學(xué);2015年
10 孫金波;腦梗死患者血清Aβ水平及他汀類藥物對(duì)其影響作用的研究[D];山東大學(xué);2008年
,本文編號(hào):2413234
本文鏈接:http://www.sikaile.net/yixuelunwen/shenjingyixue/2413234.html